CA-SCIENTIST.COM
9.4.2024 13:56:31 CEST | Business Wire | Press release
Scientist.com, the pharmaceutical industry’s leading R&D marketplace, announced today that Sanguine Biosciences, a leading biospecimen provider that connects researchers to the biospecimens they need with a direct-to-donor model to accelerate precision medicine and cell and gene therapy research and development, has successfully completed a VERIF.i® on-site assessment. VERIF.i helps Scientist.com marketplace suppliers demonstrate internal processes and adherence to best practices to both existing and potential new clients.
“Through direct-to-donor engagement, Sanguine continues to amass one of the industry’s largest collections of ethically procured collections that includes extensive data about the biospecimens,” stated Sanguine CEO Brian Neman. “Scientist.com’s VERIF.i program enables us to further demonstrate the exceptional quality of our biospecimen and biorepository services and the commitment of our team to bridge the gap between donors and researchers.”
Sanguine supports translational, clinical, and cell and gene therapy research, and their services include prospective in-home biospecimen collection directly from their donor network, apheresis products including leukopaks and LeukoLots™, biospecimen inventory, and biorepository services. Their research products and services facilitate advanced therapy development programs from discovery to manufacturing.
“Human biological samples increasingly represent critical tools in the drug discovery and development process, but researchers in the life sciences often have difficulty finding high-quality, ethically sourced human samples,” stated Matt McLoughlin, SVP of Categories & Compliance at Scientist.com. “VERIF.i was developed to create a standardized process that helps researchers and sample providers ensure that the samples used in research meet their expected quality and ethical standards.”
For more information on VERIF.i, visit https://www.scientist.com/verifi/
About Sanguine Biosciences
Sanguine Biosciences is accelerating the adoption of personalized medicine by empowering patients with their healthcare data and facilitating participation in biomedical research. By merging annotated patient biospecimens with real-world and analytical data, Sanguine delivers actionable biomarker discovery and validation studies that bridge the gap between patients and scientists working on innovative therapies. In supporting translational and clinical research at 30 of the top 40 global pharmaceutical and biotechnology companies, Sanguine has accelerated R&D and increased confidence in drug development and manufacturing pipelines. For the past four years, Sanguine has received the prestigious designation as a "Great Places to Work'' company. In 2023, Sanguine was designated on the Inc. 5000 America's Fastest Growing Private Companies list, Fortune Best Workplaces in BioPharma, and Fortune Best Small Workplaces. Visit sanguinebio.com to learn more.
About Scientist.com
Scientist.com is a privately held San Diego-based company on a mission to make it faster and cheaper to discover new medicines. At its heart is an AI-powered marketplace that helps drug researchers use innovative technologies to rapidly translate their ideas into actionable data. Through Scientist.com, scientists communicate directly with research experts at over 4,000 global laboratories to design and execute complex research experiments. Visit scientist.com to learn more.
Join Scientist.com on social media: LinkedIn, Twitter, YouTube, Facebook and Instagram
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240409671820/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Tigo Energy and Ingeteam Sign Certificate of Compatibility25.8.2026 06:00:00 CEST | Press release
Successful testing between Tigo MLPE and Ingeteam inverters validates an open ecosystem with proven compatibility for European solar installers. Tigo Energy, Inc. (NASDAQ: TYGO), a leading provider of intelligent solar and energy solutions, today announced a Certificate of Compatibility with European energy technology leader, Ingeteam S.A., documenting which Ingeteam inverters and Tigo Flex MLPE products have passed compatibility testing. The certificate covers certain single-phase and three-phase INGECON® SUN products and members of the Tigo TS4 MLPE product family, when properly designed and installed. Together, these products are designed to deliver high-quality, enhanced value with a system that can generate and manage solar energy more efficiently and provide the features that solar energy customers in the residential, Commercial and Industrial (C&I) and Utility segments demand. Ingeteam, a leading decarbonization and energy transformation company building a sustainable future thr
Celltrion Expands Omlyclo® Portfolio in Europe with Launch of 300 mg Strength25.8.2026 00:40:00 CEST | Press release
Omlyclo® (omalizumab) 300 mg launched in key European markets including Germany, the UK and France, with rollout to expand across Europe by year-endOmlyclo® 300 mg strength available in both pre-filled syringe (PFS) and autoinjector (AI) presentationsMultiple dose strengths and device options broaden treatment flexibility for healthcare professionals Celltrion (KRX: 068270) today announced the launch of the 300 mg strength of Omlyclo® (omalizumab), a treatment for chronic spontaneous urticaria and allergic asthma, in Europe.1 With the addition of the 300 mg strength, Celltrion has expanded its Omlyclo® portfolio to include multiple dose strengths and device presentations for patients, healthcare professionals and healthcare institutions. Following the European launch of Omlyclo® 75 mg and 150 mg late last year, Celltrion began rolling out the 300 mg strength in key markets including Germany, the UK and France in the middle of this year. Celltrion is gradually expanding supply to other
Fourthline Trust Services Granted Status as Qualified Trust Service Provider in the EU24.8.2026 15:13:00 CEST | Press release
QTSP status allows for full control over the digital trust value chain from identity verification to qualified electronic signature (QES) issuance Fourthline Trust Services AB, a subsidiary of Fourthline, has been granted qualified status under the EU's eIDAS Regulation (910/2014)¹ and is now listed on the EU Trusted List as a Qualified Trust Service Provider (QTSP). Supervised by the Swedish Post and Telecom Authority (Post- och telestyrelsen, PTS), Fourthline Trust Services AB issues qualified certificates for electronic signatures. Fourthline, is the leading European provider of AI-powered identity verification (IDV) and compliance solutions. This milestone allows Fourthline full control over the entire digital trust value chain from identity verification to qualified electronic signature (QES) issuance. Ralph Post, Fourthline Trust Services AB Board Member: "By building our QTSP infrastructure similar to our sovereign AI-powered platform that drives our industry-leading identity ve
SLB Launches ExaCT Electrical Downhole CT Control System24.8.2026 13:02:00 CEST | Press release
New platform brings real-time electrical control to coiled tubing intervention, enabling greater precision, visibility and efficiency across intervention operations SLB (NYSE: SLB) today launched the ExaCT™ electrical downhole coiled tubing (CT) control system, an advanced intervention platform that introduces real-time electrical control to coiled tubing operations. By replacing pressure-dependent hydraulic actuation with electrical communication, power delivery and telemetry, the ExaCT system gives operators greater visibility, precision and control, helping improve intervention execution and reservoir access. The ExaCT system combines electrical power, telemetry and downhole measurements to enable communication with, actuation of and verification of downhole tools throughout an intervention. Continuous communication across the toolstring enables on-demand tool actuation across a wide range of intervention applications, including extended-reach and multilateral wells. The increased p
Wolters Kluwer Transforms Trusted Legal Content Into Structured, AI-Ready Intelligence That Powers the Next Wave of Legal AI24.8.2026 13:01:00 CEST | Press release
By transforming authoritative legal content into structured legal intelligence, Wolters Kluwer gives AI the context and relationships needed to deliver deeper research and higher-quality results Wolters KluwerLegal & Regulatory today announced the next evolution of Libra by Wolters Kluwer, its all-in-one Legal AI Workspace. By transforming authoritative legal sources, expert commentaries, and practical guidance into structured legal intelligence, Wolters Kluwer is making the relationships across the full breadth of its expert legal sources more explicit. This will enable deeper contextual research, more comprehensible answers, and workflow-ready results across legal work. Following the integration of Wolters Kluwer content into the Libra AI workspace in the first half of 2026, laws, rulings, expert commentaries, and practical guidance will now be linked to one another and to the matter at hand, creating a connected knowledge graph of expert-curated and authoredlegal knowledge that AI c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom